• Azora Therapeutics appointed co-founder Matt Davidson president and CEO effective October 28, 2026; he previously founded Verrica Pharmaceuticals.
• Other appointments included Celia Economides, a biopharma finance veteran, as CFO; co-founder Julie Saiki, whose Stanford research underpinned AT177, became chief strategy officer.
• David Rubenstein joined as chief scientist; he previously served as Dermavant Sciences’ chief scientific officer, leading tapinarof development.
• Independent directors appointed November 3 included Aida Habtezion, Pfizer’s former chief medical officer; Paul Hastings, Nkarta’s CEO, also joined.
• Thomas Soloway, T-knife Therapeutics’ CEO and former CFO of Audentes Therapeutics and Ascendis Pharma, also joined the board, chairing the Audit Committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876672) on November 12, 2026, and is solely responsible for the information contained therein.